Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClasticTM ASO Platform

AI Briefing

• – Alloy Therapeutics and Biogen collaborate on using AntiClastic ASO Platform for multiple targets.
• – Biogen to advance antisense therapeutics against undisclosed targets.
• – Alloy to receive upfront payment.